CagriSema REDEFINE 9: what the lower-dose results tell us
New results explore two lower doses of investigational CagriSema. The study supports comparison with placebo, but cannot establish which dose is better.
Read the story ↗Health compare UK · clarity starts here
Understand your options for obesity care in the UK.
Compare pharmacy prices, explore the evidence, and see the bigger picture.
Compare the published costs at 85 UK pharmacies. Look beyond the introductory price to the cost of continuing care.
How we compare prices ↗tirzepatide
semaglutide
oral semaglutide
orforglipron
Latest source read: 19 November 2026 at 07:07. Individual lists show their own dates. First-order offers have conditions. Check delivery charges with the provider. Medicines are not interchangeable; treatment requires a prescriber’s assessment.
Finding support for your health can feel like joining a conversation halfway through. We explain the terms, separate the decisions, and show you where the information comes from.
Medicine news with the context that matters for UK readers. What changed, what remains uncertain, and what it means for access here.
All research & news ↗New results explore two lower doses of investigational CagriSema. The study supports comparison with placebo, but cannot establish which dose is better.
Read the story ↗Recent company reports describe further phase 3 findings. Retatrutide remains investigational, and the population and comparator matter when interpreting its results.
Read the story ↗Orforglipron, branded Foundayo, received UK authorisation in August 2026. A tablet changes the treatment routine, but assessment, monitoring and access decisions still matter.
Read the story ↗Our comparisons start in the UK. Our curiosity goes further. Explore how obesity care, regulation and funding differ around the world — and why overseas headlines do not always translate into UK access.
Explore the country guides ↗Sources you can open. Dates you can check. Clear limits on what a comparison can tell you.
Yes. Health Comparisons is written for people in the UK. Our pharmacy comparisons use UK providers and prices in pounds sterling. International articles provide context and do not describe UK eligibility.
No. We publish comparisons and information. A qualified prescriber must assess whether a treatment is appropriate, and the pharmacy sets its own consultation and supply requirements.
A price table cannot answer that. Consider the assessment, follow-up, delivery, terms and registration details alongside the total cost. A listed price does not establish stock or treatment suitability.
They explain published evidence and regulatory announcements. We distinguish research findings from authorised treatment and NHS funding, and link the sources so you can examine the original information.